Avalo Therapeutics to Attend Upcoming Investor Conferences

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Aug 26 2025

0mins

Source: Globenewswire

Investor Conferences Participation: Avalo Therapeutics will participate in several upcoming investor conferences, including the Cantor Global Healthcare Conference on September 3, H.C. Wainwright Annual Global Investment Conference on September 9, and Stifel Virtual Immunology Forum on September 15.
Webcast Availability: Live webcasts of these events will be accessible on Avalo's website, with archived versions available for at least 30 days.
Company Focus: Avalo Therapeutics is dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, with its lead asset, AVTX-009, currently in a Phase 2 clinical trial for hidradenitis suppurativa.
About AVTX-009: AVTX-009 is a humanized monoclonal antibody that targets interleukin-1β, a key pro-inflammatory cytokine involved in various autoimmune disorders, aiming to reduce inflammation and improve treatment outcomes.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free